Verteporfin is indicated for the treatment of adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or adults with subfoveal choroidal neovascularisation secondary to pathological myopia. Verteporfin is also used in the treatment of ocular cancer in specialist centres.

Verteporfin is used off-label for the management of central serous retinopathy with photodynamic therapy.

Verteporfin has been in short supply globally since late 2020 due to capacity constraints at the manufacturing site. The issue is not expected to resolve until the middle of 2024.

This National Patient Safety Alert provides further background and clinical information and actions for providers.